Hemostemix Awards 6.28 Million Stock Options to Key Personnel and Consultants

Option Vesting Schedule and Allocation Breakdown

The granted 6,280,000 stock options feature a dual vesting schedule: 4,535,000 options vest immediately, enabling instant equity participation, while 1,745,000 options vest 50% on July 22, 2026, and the remaining 50% on July 22, 2027. This arrangement balances immediate rewards with incentives for long-term retention. Approximately 72% of the options vest immediately, with the remaining 28% subject to deferred vesting. The announcement did not specify exercise prices or other option terms.

Recipients and Governance Approval

Half of the options (3,140,000) were granted to Hemostemix's directors and officers, with the other half distributed among employees and consultants. This equitable distribution aligns the interests of leadership with those of staff and external partners. The grant received unanimous approval from both the Compensation Committee and the Board of Directors, with no dissenting or abstaining votes reported.

Regulatory Compliance and Exemptions Under MI 61-101

Hemostemix utilized exemptions under Multilateral Instrument 61-101 (MI 61-101) for this options grant. Specifically, section 5.5(b) exempted the company from formal valuation requirements, as no securities are listed on a specified market defined by MI 61-101. Additionally, section 5.7(a) exempted the company from minority shareholder approval since the fair market value of the options and consideration did not exceed 25% of Hemostemix’s market capitalization. These provisions ensure regulatory compliance without triggering additional approval thresholds.

Material Change Report Timing

The company disclosed that the material change report related to this options grant was not filed at least 21 days before completion, as typically required by MI 61-101. Hemostemix justified this shorter filing period as reasonable and necessary, given the grant’s completion shortly before the announcement. This accelerated timeline is permitted under MI 61-101 when appropriately justified, and the company’s transparency fulfills market disclosure obligations.

Company Overview and VesCell™ Therapy Development

Founded in 2003, Hemostemix is an autologous stem cell therapy platform company developing VesCell™, an investigational therapy supporting circulation in ischemia-affected areas. Derived from patients’ own blood, VesCell™ has been studied in clinical programs targeting peripheral arterial disease, chronic limb threatening ischemia, non-ischemic and ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix has conducted seven clinical studies involving 318 subjects, with findings published in eleven peer-reviewed journals. The company earned the World Economic Forum Technology Pioneer Award, underscoring its innovation leadership.

Clinical Trial Outcomes and Efficacy Highlights

Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia (CLTI), with results published in the Journal of Biomedical Research & Environmental Science. Interim data presented at the 41st vascular surgeons meeting by researchers from the University of British Columbia and University of Toronto showed zero mortality, pain cessation, and 83% wound healing among patients followed up to 4.5 years. This contrasts with an approximate 50% five-year mortality rate in the CLTI diabetic population, highlighting the therapy’s potential impact. Additional trial details such as patient numbers, geographic scope, or control groups were not disclosed.

Impact on Equity Structure and Dilution

Following this grant, Hemostemix’s total outstanding stock options stand at 20,496,694. This figure represents the full option pool under the company’s stock option plan as of July 22, 2026. The size of the outstanding options is a key consideration for investors assessing potential dilution, as exercising these options would increase the number of common shares. The announcement did not provide the total common shares outstanding, option exercise prices, or dilution percentages, which can be found in other regulatory filings on SEDAR+.

Market Presence and Industry Recognition

Hemostemix’s status as a World Economic Forum Technology Pioneer Award recipient highlights its standing in global health innovation. The company is listed on the TSX Venture Exchange (TSXV:HEM), OTC Markets (OTCQB: HMTXF), and Frankfurt Stock Exchange (FSE: 2VF0), reflecting its access to Canadian and international capital markets. The announcement did not disclose recent trading volumes, market capitalization, or share price trends.

Strategic Purpose of the Stock Option Program

The allocation of 6,280,000 stock options across directors, officers, employees, and consultants demonstrates Hemostemix’s broad-based equity incentive strategy. Allocating 50% of options to directors and officers aligns leadership compensation with shareholder interests, while grants to employees and consultants support talent retention and external expertise engagement. Immediate vesting of 72% of options offers prompt equity participation, with the remaining 28% vesting later to encourage ongoing commitment. The company did not disclose specific business reasons for the July 22, 2026 grant timing or its relation to corporate milestones or fiscal periods.